MOMORDICA CHARANTIA
Has been shown to exert hypoglycemic effects by enhancing glucose uptake, improving insulin secretion, and reducing insulin resistance. Its bioactive compounds-such as charantin, vicine, and polypeptide-p-act on various metabolic pathways involved in blood glucose regulation.
Bitter melon also demonstrates antioxidant and anti-inflammatory activity, helping to protect pancreatic β-cells and reduce oxidative stress associated with diabetes complications.Clinical and preclinical studies suggest that regular supplementation may support improved glycemic control in individuals with type 2 diabetes.
References:
Zhang X, Zhao Y, Song Y, Miao M. Effects of Momordica charantia L. supplementation on glycemic control and lipid profile in type 2 diabetes mellitus patients: A systematic review and meta-analysis of randomized controlled trials. Heliyon. 2024 May 11;10(10):e31126.
Fuangchan A, Sonthisombat P, Seubnukarn T, Chanouan R, Chotchaisuwat P, Sirigulsatien V, Ingkaninan K, Plianbangchang P, Haines ST. Hypoglycemic effect of bitter melon compared with metformin in newly diagnosed type 2 diabetes patients. J Ethnopharmacol. 2011 Mar 24;134(2):422-8.
Kim SK, Jung J, Jung JH, Yoon N, Kang SS, Roh GS, Hahm JR. Hypoglycemic efficacy and safety of Momordica charantia (bitter melon) in patients with type 2 diabetes mellitus. Complement Ther Med. 2020 Aug;52:102524.
oseph B, Jini D. Antidiabetic effects of Momordica charantia (bitter melon) and its medicinal potency. Asian Pac J Trop Dis. 2013 Apr;3(2):93–102.
